Transungual delivery of terbinafine by iontophoresis in onychomycotic nails

Drug Development and Industrial Pharmacy

Volumn 37, Issue 10, 2011, Pages 1253-1258

  Nair, Anroop B ^a   Kiran Vaka, Siva Ram ^b   Murthy, S Narasimha ^b  

^a MAHARISHI MARKANDESHWAR DEEMED TO BE UNIVERSITY   (India)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Drug release; Iontophoresis; Microscopy; Onychomycotic nails; Terbinafine

Indexed keywords

AGAR; POTASSIUM HYDROXIDE; TERBINAFINE;

ADULT; AGAR DIFFUSION; AGED; ARTICLE; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG PENETRATION; DRUG RELEASE; FEMALE; FINGERNAIL ONYCHOMYCOSIS; HUMAN; IN VITRO STUDY; IONTOPHORESIS; MALE; PASSIVE TRANSPORT; STEADY STATE; TOENAIL ONYCHOMYCOSIS; TRANSUNGUAL DRUG DELIVERY;

ANTIFUNGAL AGENTS; DRUG DELIVERY SYSTEMS; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; IONTOPHORESIS; NAPHTHALENES; ONYCHOMYCOSIS; PERMEABILITY;

EID: 80052456636     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2011.568946     Document Type: Article

References (20)

1. Elewski BE. (1998). Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev, 11:415-429 (Pubitemid 28379092)
2. Evans EG. (1998). Causative pathogens in onychomycosis and the possibility of treatment resistance: a review. J Am Acad Dermatol, 38:S32-S36 (Pubitemid 28215620)
3. Finch JJ, Warshaw EM. (2007). Toenail onychomycosis: current and future treatment options. Dermatol Ther, 20:31-46 (Pubitemid 46568375)
4. Roberts DT. (1999). Onychomycosis: current treatment and future challenges. Br J Dermatol, 141 (Suppl 56):1-4
5. Sigurgeirsson B, Steingrímsson O. (2004). Risk factors associated with onychomycosis. J Eur Acad Dermatol Venereol, 18:48-51 (Pubitemid 38159359)
6. Gupta AK, Shear NH. (2000). A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis. Drug Saf, 22:33-52 (Pubitemid 30058026)
7. Millikan LE, Powell DW, Drake LA. (1999). Quality of life for patients with onychomycosis. Int J Dermatol, 38 (Suppl 2):13-16 (Pubitemid 29469841)
8. Effendy I. (1995). Therapeutic strategies in onychomycosis. J Eur Acad Dermatol Venerol, 4:S3-S10
9. Piérard GE, Arrese JE, Quatresooz P, Piérard-Franchimont C. (2007). Emerging therapeutic agents for onychomycosis. Expert Opin Emerg Drugs, 12:345-353 (Pubitemid 47518372)
10. Arrese JE, Piérard GE. (2003). Treatment failures and relapses in onychomycosis: a stubborn clinical problem. Dermatology (Basel), 207:255-260 (Pubitemid 37329194)
11. Baran R, Kaoukhov A. (2005). Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol, 19:21-29 (Pubitemid 40268136)
12. Murdan S. (2002). Drug delivery to the nail following topical application. Int J Pharm, 236:1-26 (Pubitemid 34219369)
13. Bodman MA, Feder L, Nace AM. (2003). Topical treatments for onychomycosis: a historical perspective. J Am Podiatr Med Assoc, 93:136-141 (Pubitemid 38469493)
14. Nair AB, Kim HD, Chakraborty B, Singh J, Zaman M, Gupta A et al. (2009). Ungual and trans-ungual iontophoretic delivery of terbinafine for the treatment of onychomycosis. J Pharm Sci, 98:4130-4140
15. Nair AB, Vaka SR, Sammeta SM, Kim HD, Friden PM, Chakraborty B et al. (2009). Trans-ungual iontophoretic delivery of terbinafine. J Pharm Sci, 98:1788-1796
16. Scher RK. (1996). Onychomycosis: a significant medical disorder. J Am Acad Dermatol, 35:S2-S5
17. Dykes PJ, Thomas R, Finlay AY. (1990). Determination of terbinafine in nail samples during systemic treatment for onychomycoses. Br J Dermatol, 123:481-486 (Pubitemid 20344788)
18. Dutet J, Delgado-Charro MB. (2009). In vivo transungual iontophoresis: effect of DC current application on ionic transport and on transonychial water loss. J Control Release, 140:117-125
19. Faergemann J, Zehender H, Denouël J, Millerioux L. (1993). Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks. Acta Derm Venereol, 73:305-309 (Pubitemid 23282980)
20. Hui X, Shainhouse Z, Tanojo H, Anigbogu A, Markus GE, Maibach HI et al. (2002). Enhanced human nail drug delivery: nail inner drug content assayed by new unique method. J Pharm Sci, 91:189-195 (Pubitemid 34074477)